11:11 AM EDT, 09/09/2024 (MT Newswires) -- Xencor ( XNCR ) shares jumped 17% in recent Monday trading after the company unveiled four new drug candidates for the treatment of autoimmune and inflammatory diseases and disclosed clinical progress updates in its early-stage oncology programs.

Plamotamab (CD20 x CD3), XmAb657 (CD19 x CD3), XmAb942 (Xtend TL1A) andXmAb TL1A x IL-23 programs have studies expected to start in H1 2025, H2 2025, Q4 2024 and in 2026, respectively, the company said Monday in a statement

On the updates for the oncology programs. initial evidence of anti-tumor activity has been observed in recent dose-escalation groups with XmAb819 (ENPP3 x CD3), the company said.

For XmAb808 (B7-H3 x CD28), prostate specific antigen declines have been observed during the four-week monotherapy safety run-in period in a group of patients, the company said.

Price: 19.00, Change: +2.82, Percent Change: +17.43